Anemia is one of the many complications of chronic kidney disease (CKD). However, the current prevalence of anemia in\r\nCKD patients in the United States is not known. Data from the National Health and Nutrition Examination Survey (NHANES)\r\nin 2007ââ?¬â??2008 and 2009ââ?¬â??2010 were used to determine the prevalence of anemia in subjects with CKD. The analysis was\r\nlimited to adults aged .18 who participated in both the interview and exam components of the survey. Three outcomes\r\nwere assessed: the prevalence of CKD, the prevalence of anemia in subjects with CKD, and the self-reported treatment of\r\nanemia. CKD was classified into 5 stages based on the glomerular filtration rate and evidence of kidney damage, in\r\naccordance with the guidelines of the National Kidney Foundation. Anemia was defined as serum hemoglobin levels #12 g/\r\ndL in women and #13 g/dL in men. We found that an estimated 14.0% of the US adult population had CKD in 2007ââ?¬â??2010.\r\nAnemia was twice as prevalent in people with CKD (15.4%) as in the general population (7.6%). The prevalence of anemia\r\nincreased with stage of CKD, from 8.4% at stage 1 to 53.4% at stage 5. A total of 22.8% of CKD patients with anemia\r\nreported being treated for anemia within the previous 3 monthsââ?¬â??14.6% of patients at CKD stages 1ââ?¬â??2 and 26.4% of patients\r\nat stages 3ââ?¬â??4. These results update our knowledge of the prevalence and treatment of anemia in CKD in the United States.
Loading....